Patterns of Systemic Antifungal Initiation Across Ordinary, COVID-19, and Earthquake-Affected ICU Cohorts: A Retrospective Single-Center Study

Background: Systemic antifungal treatment in intensive care units (ICUs) is frequently initiated before microbiological confirmation. Earthquake-affected ICUs provide an important setting for examining antifungal decision-making under sudden patient surges and disrupted care processes. We compared initiation patterns across ordinary pre-pandemic, COVID-19, and earthquake-affected ICU cohorts. Methods: This retrospective single-center study included 566 adults receiving systemic antifungal therapy for suspected or blood-culture-confirmed Candida bloodstream infection: 256 ordinary pre-pandemic, 150 COVID-19, and 160 earthquake-affected patients. Initiation was classified as empirical, culture-guided, or same-day indeterminate using the recorded ICU days of treatment initiation and blood culture positivity. Initial antifungal class, documented infectious diseases consultation, and total treatment duration were compared. Thirty-day all-cause mortality after antifungal initiation was a secondary exploratory outcome. Results: Initiation patterns differed across cohorts (p < 0.001; Cramer’s V = 0.449). Empirical initiation occurred in 15.6%, 85.3%, and 69.4% of ordinary, COVID-19, and earthquake-affected patients, respectively. Echinocandins accounted for 96.0% of initial therapy in the COVID-19 cohort. Infectious diseases consultation was documented in 80.5%, 66.7%, and 19.4%, respectively. Median treatment durations were 8 (interquartile range, 6–10), 8 (4–14), and 6 (5–7) days (p < 0.001). After excluding 63 same-day cases, empirical initiation was not significantly associated with mortality after adjustment (adjusted odds ratio, 0.891; 95% confidence interval, 0.522–1.519; p = 0.671). Alternative same-day classifications also yielded nonsignificant associations. Conclusions: Recorded antifungal initiation timing and treatment patterns differed across the three ICU cohorts. These descriptive findings do not establish causal effects of healthcare context, treatment appropriateness, or equivalence between initiation approaches.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-01
DOI
https://doi.org/10.3390/antibiotics15111083
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patterns of Systemic Antifungal Initiation Across Ordinary, COVID-19, and Earthquake-Affected ICU Cohorts: A Retrospective Single-Center Study

Mustafa Zafer Uğuz, Berfin Çirkin Doruk
Antibiotics
Antifungal resistance and susceptibility
article

Patterns of Systemic Antifungal Initiation Across Ordinary, COVID-19, and Earthquake-Affected ICU Cohorts: A Retrospective Single-Center Study

Mustafa Zafer Uğuz, Berfin Çirkin Doruk
article en

Abstract

Background: Systemic antifungal treatment in intensive care units (ICUs) is frequently initiated before microbiological confirmation. Earthquake-affected ICUs provide an important setting for examining antifungal decision-making under sudden patient surges and disrupted care processes. We compared initiation patterns across ordinary pre-pandemic, COVID-19, and earthquake-affected ICU cohorts. Methods: This retrospective single-center study included 566 adults receiving systemic antifungal therapy for suspected or blood-culture-confirmed Candida bloodstream infection: 256 ordinary pre-pandemic, 150 COVID-19, and 160 earthquake-affected patients. Initiation was classified as empirical, culture-guided, or same-day indeterminate using the recorded ICU days of treatment initiation and blood culture positivity. Initial antifungal class, documented infectious diseases consultation, and total treatment duration were compared. Thirty-day all-cause mortality after antifungal initiation was a secondary exploratory outcome. Results: Initiation patterns differed across cohorts (p < 0.001; Cramer’s V = 0.449). Empirical initiation occurred in 15.6%, 85.3%, and 69.4% of ordinary, COVID-19, and earthquake-affected patients, respectively. Echinocandins accounted for 96.0% of initial therapy in the COVID-19 cohort. Infectious diseases consultation was documented in 80.5%, 66.7%, and 19.4%, respectively. Median treatment durations were 8 (interquartile range, 6–10), 8 (4–14), and 6 (5–7) days (p < 0.001). After excluding 63 same-day cases, empirical initiation was not significantly associated with mortality after adjustment (adjusted odds ratio, 0.891; 95% confidence interval, 0.522–1.519; p = 0.671). Alternative same-day classifications also yielded nonsignificant associations. Conclusions: Recorded antifungal initiation timing and treatment patterns differed across the three ICU cohorts. These descriptive findings do not establish causal effects of healthcare context, treatment appropriateness, or equivalence between initiation approaches.

AntibioticsVol. 15(11)
Mersin Şehir Eğitim ve Araştırma Hastanesi (TR)
Openalex Percentile: Top 12%
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon